Kirubel Tefera1, John Breneman2, Katheleen Marie Woeste1, Chandana Kamireddy1 and Tahir Latif1*
1Department of Medicine, University of Cincinnati, USA
2Department of Radiation Oncology, University of Cincinnati, USA
The Central Nervous System (CNS) is one of the common sites of metastasis for advanced lung cancer. CNS metastases often cause significant morbidity and survival after diagnosis is dismal. Though stereotactic radio surgery has improved the outlook for some of these patients, there remains a need to develop additional therapies to control brain disease, especially with recent advancements in control of extra-CNS tumor. Systemic chemotherapy with Bevacizumab, an angiogenesis inhibitor, has shown promising activity in metastatic non-small cell lung cancer. Studies have shown that initial concern for excessive risk of CNS bleeding was unfounded and bevacizumab is now approved as second line treatment for glioblastoma. Here we present a case of metastatic lung cancer to the brain treated with multiple local and systemic therapies including Bevacizumab with over 4 years of control of his CNS disease. We also review the evidence regarding the safety and efficacy of Bevacizumab in this setting.
Bevacizumab; CNS metastasis; NSCLC; Vascular endothelial growth factor
Tefera K, Breneman J, Woeste KM, Kamireddy C, Latif T. Long term Control of Metastatic Adenocarcinoma of the Lung to the Brain with Radiotherapy, Systemic Chemotherapy and Bevacizumab. Ann Clin Case Rep. 2019; 4: 1593.